Safeguarding children's rights in psychopharmacological research: Ethical and legal issues

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2398-2406

  Kölch, Michael ^a   Ludolph, Andrea G ^a   Plener, Paul L ^a   Fangerau, Heiner ^b   Vitiello, Benedetto ^c   Fegert, Joerg M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Children and adolescents; Ethics; Psychopharmacology; Research

Indexed keywords

CHILD; DRUG LEGISLATION; HUMAN; INFORMED CONSENT; LEGAL ASPECT; MEDICAL ETHICS; MEDICOLEGAL ASPECT; PATIENT RIGHT; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

ADOLESCENT; BIOMEDICAL RESEARCH; CHILD; CLINICAL TRIALS AS TOPIC; CODES OF ETHICS; CONFLICT OF INTEREST; ETHICS, MEDICAL; EUROPE; HUMANS; LEGISLATION, MEDICAL; PARENTAL CONSENT; PATIENT RIGHTS; PSYCHOPHARMACOLOGY; RISK; UNITED STATES;

EID: 77955636083     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959881     Document Type: Review

References (111)

1. Vitiello B. Ethical considerations in psychopharmacological research involving children and adolescents. Psychopharmacology (Berl) 2003; 171(1): 86-91.
2. Vitiello B, Riddle MA, Greenhill LL, et al. How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry 2003; 42(6): 634-41.
3. Vitiello B. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology (Berl) 2007; 191(1): 5-13.
4. Koelch M, Schnoor K, Fegert JM. Ethical issues in psychopharmacology of children and adolescents. Curr Opin Psychiatry 2008; 21(6): 598-605.
5. Vitiello B, Heiligenstein JH, Riddle MA, et al. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 2004; 56(1): 3-9.
6. Volkers AC, Heerdink ER, van Dijk L. Antidepressant use and offlabel prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 2007; 16(9): 1054-62.
7. Waller DG. Off-label and unlicensed prescribing for children: have we made any progress? Br J Clin Pharmacol 2007; 64(1): 1-2.
8. Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65(4): 600-6.
9. Maid G, Guerchicoff M, Falconi M, et al. Written consent to use the drug in children: the problem of off-label drugs. Curr Pharm Des 2008; 14(8): 776-81.
10. Tan JO, Koelch M. The ethics of psychopharmacological research in legal minors. Child Adolesc Psychiatry Ment Health 2008; 2(1): 39.
11. Shearer MC, Bermingham SL. The ethics of paediatric antidepressant use: erring on the side of caution. J Med Ethics 2008; 34(10): 710-4.
12. Sparks JA, Duncan BL. The ethics and science of medicating children. Ethical Hum Psychol Psychiatry 2004; 6(1): 25-39.
13. Mukattash TL, Millership JS, Collier PS, et al. Public awareness and views on unlicensed use of medicines in children. Br J Clin Pharmacol 2008; 66(6): 838-45.
14. Morales-Olivas FJ, Morales-Carpi C. Clinical trials in children. Rev Recent Clin Trials 2006; 1(3): 251-8.
15. Fangerau H. Finding European bioethical literature: an evaluation of the leading abstracting and indexing services. J Med Ethics 2004; 30(3): 299-303.
16. National commission for the protection of human to biomedical and beavioral research. The Belmont report ethical principles and guidelines for the protection of human subjects of research. Department of Health, Education, and Welfare 1979.
17. Lee L. Ethical issues related to research involving children. J Pediat Oncol Nurs 1991; 1(8): 24-9.
18. World Medical Association. Declaration of helsinki: ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975, 35th WMA General Assembly, Venice, Italy, October 1983. 41st WMA General Assembly, Hong Kong, September 1989, 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996, and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Note of Clarification on Paragraph 29 added by the WMA General Assembly, Washington 2002. Note of Clarification on Paragraph 30 added by the WMA General Assembly, Tokyo 2004, 59th WMA General Assembly, Seoul, October 2008.
19. Food and Drug Administration. In: Register F, Ed. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients: final rule. 1998; pp. 66631-72.
20. Koelch M, Lippert HD, Fegert JM. The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations. Z Kinder Jugendpsychiatr Psychother 2006; 34(2): 117-26.
21. Koelch M, Schnoor K, Fegert J. The EU-regulation on medicinal products for paediatric use. Impacts on child and adolescent psychiatry and clinical research with minors. Eur Child Adolesc Psychiatry 2007; 16(4): 229-35.
22. Baldwin D, Broich K, Fritze J, et al. Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatr Clin Neurosci 2003; 253(1): 22-8.
23. Broich K. Clinical trials using antidepressants and antipsychotics. The pros and cons of placebo control. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005; 48(5): 541-7.
24. March J, Kratochvil C, Clarke G, et al. AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2004; 43(8): 1046-56.
25. Pinxten W, Dierickx K, Nys H. The implementation of Directive 2001/20/EC into Belgian law and the specific provisions on pediatric research. Eur J Health Law 2008; 15(2): 153-61.
26. Kenter MJ. Legislation and review of medical research with minors in The Netherlands. Eur J Health Law 2008; 15(2): 145-51.
27. Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther 2007; 81(4): 477-9.
28. Food & Drug Administration. Approved moieties to which FDA has granted pediatric exclusivity for pediatric studies under section 505A of the Federal Food, Drug and Cosmetic Act. Available at: http://www.fda.gov/cder/pediatric/exgrant.htm, accessed July 19, 2006. 2003 [cited; Available from: http://www.fda.gov/cder/ediatric/exgrant.htm
29. Klein DF. The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 2006; 31(4): 689-99.
30. Schubert S, Lippert HD, Fegert JM, et al. Industrieunabhängige Forschung an Kindern und die 12. Novelle des Arzneimittelgesetzes. Monatsschrift Kinderheilkunde 2007; 155(2): 152-6.
31. Kölch M, Märsch C, Fegert JM, et al. Klinische Prüfungen mit Arzneimitteln in Deutschland an Minderjährigen - Auswirkungen der 12. Novelle zum AMG auf das Antragsaufkommen bei den Ethikkommissionen. Das Gesundheitswesen 2009; 71: 127-33.
32. Malhotra S, Subodh BN. Informed consent & ethical issues in paediatric psychopharmacology. Indian J Med Res 2009; 129(1): 19-32.
33. Tan JO, Fegert JM. Capacity and competence in child and adolescent psychiatry. Health Care Anal 2004; 12(4): 285-94; discussion 265-72.
34. Tan JO, Hope T. Mental health legislation and decision making capacity: capacity is more complex than it looks. BMJ 2006; 332(7533): 119.
35. Tan J, Hope T, Stewart A. Competence to refuse treatment in anorexia nervosa. Int J Law Psychiatry 2003; 26(6): 697-707.
36. Billick SB, Edwards JL, Burgert W, et al. A clinical study of competency in child psychiatric inpatients. J Am Acad Psychiatry Law 1998; 26(4): 587-94.
37. Wagner KD, Martinez M, Joiner T. Youths' and their parents' attitudes and experiences about participation in psychopharmacology treatment research. J Child Adolesc Psychopharmacol 2006; 16(3): 298-307.
38. Vitiello B, Kratochvil CJ, Silva S, et al. Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2007; 46(12): 1642-50.
39. Koelch M, Singer H, Prestel A, et al. because I am something special or I think I will be something like a guinea pig: information and assent of legal minors in clinical trials - assessment of understanding, appreciation and reasoning. Child Adolesc Psychiatr Ment Health 2009; 3(1): 2.
40. Ondrusek N, Abramovitch R, Pencharz P, et al. Empirical examination of the ability of children to consent to clinical research. J Med Ethics 1998; 24(3): 158-65.
41. Kon AA. Assent in pediatric research. Pediatrics 2006; 117(5): 1806-10.
42. Koelch M, Prestel A, Singer H, et al. Report of an initial pilot study on the feasability of using macarthur competence assessment tool for clinical research for children and adolescents with attention-deficit/hyperacitvity-disorder. J Child Adolesc Psychopharmacol 2010; 20 (1): 63-7.
43. Tait AR, Voepel-Lewis T, Malviya S. Do they understand? (part II): assent of children participating in clinical anesthesia and surgery research. Anesthesiology 2003; 98(3): 609-14.
44. U.S. Department of Health and Human Services. Protection of human subjects. Subpart D: additional protections for children involved as subjects in research. Public Welfare. Part 46 ed. 1983; pp. Subpart D: 46.401-46.409.
45. European Parliament and of the Council. EU Directive 2001/20 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Commun 2001.
46. Sammons HM, Choonara I. Clinical trials of medication in children, 1996-2002. Eur J Clin Pharmacol 2005; 61(2): 165-7.
47. Westra AE, Engberts DP, Sukhai RN, et al. Drug development for children: how adequate is the current European ethical framework? Arch Dis Child 2009; 95(1): 3-6.
48. Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch Dis Child 2009; 94(6): 474-7.
49. Klinkhammer G. Medizinische Ethikkommissionen: "Minimale Belastung und minimales Risiko". Deutsches Ärzteblatt 2006; 103(49): A-3310/B-2885/C-2765.
50. Mehler-Wex C, Kölch M, Kirchheiner J, et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatr Ment Health 2009; 3: 14.
51. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003; 348(6): 538-49.
52. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-91.
53. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29(3): 192-209.
54. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704.
55. Haga SB, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet Med 2008; 10(6): 391-5.
56. Paul NW, Fangerau H. Why should we bother? Ethical and social issues in individualized medicine. Curr Drug Targets 2006; 7(12): 1721-7.
57. Lee S, Mudaliar A. Racing Forward: The genomics and personalized medicine act. Natl Inst Health Public Access 2009; 323(5912): 342.
58. Holm S. Pharmacogenetics, race and global injustice. Dev World Bioeth 2008; 8(2): 82-8.
59. Sillon G, Joly Y, Feldman S, et al. An ethical and legal overview of pharmacogenomics: perspectives and issues. Med Law 2008; 27(4): 843-57.
60. Avard D, Silverstein T, Sillon G, et al. Researchers' perceptions of the ethical implications of pharmacogenomics research with children. Public Health Genomics 2009; 12(3): 191-201.
61. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37(6): 243-65.
62. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77(1): 1-16.
63. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104(3): 173-92.
64. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3(1): 89-98.
65. Fava M. Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1996; 35(10): 1292-303.
66. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001; 22(1): 60-73.
67. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitivebehavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292(7): 807-20.
68. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335(7611): 142. Epub 2007 Jun 7.
69. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48(5): 484-500.
70. Banaschewski T, Buitelaar J, Coghill DR, et al. The MTA at 8. J Am Acad Child Adolesc Psychiatry 2009; 48(11): 1120-1; author reply 1123-4.
71. March J, Silva S, Curry J, et al. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009; 166(10): 1141-9.
72. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363(9418): 1341-5.
73. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166(4): 418-26.
74. Frank E, Novick DM, Kupfer DJ. Beyond the question of placebo controls: ethical issues in psychopharmacological drug studies. Psychopharmacology (Berl) 2003; 171(1): 19-26.
75. Derivan AT, Leventhal BL, March J, et al. The ethical use of placebo in clinical trials involving children. J Child Adolesc Psychopharmacol 2004; 14(2): 169-74.
76. Santosh PJ, Taylor E, Swanson J, et al. Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of the multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 2005(5): 307-314.
77. Parens E, Johnston J. Understanding the agreements and controversies surrounding childhood psychopharmacology. Child Adolesc Psychiatr Ment Health 2008; 2(1): 5.
78. Parens E, Johnston J. Facts, values, and Attention-Deficit Hyperactivity Disorder (ADHD): an update on the controversies. Child Adolesc Psychiatr Ment Health 2009; 3(1): 1.
79. Spielmans IG. The promotion of olanzapine in primary care: An examination of internal industry documents. Soc Sci Med 2009; 69(1): 14-20.
80. Burke MG. SSRIs for difficult temperament. J Am Acad Child Adolesc Psychiatry 1998; 37(10): 1008-9.
81. Holtmann M, Goth K, Wockel L, et al. CBCL-pediatric bipolar disorder phenotype: severe ADHD or bipolar disorder? J Neural Transm 2008; 115(2): 155-61.
82. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70(10): 1441-51.
83. Kuehn BM. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. JAMA 2009; 302(8): 833-4.
84. Cooley D. Good enough for the Third World. J Med Philos 2000; 25(4): 427-50.
85. Cooley DR. Distributive justice and clinical trials in the Third World. Theor Med Bioeth 2001; 22(3): 151-67.
86. Sturm R, Ringel JS, Andreyeva T. Geographic disparities in children's mental health care. Pediatrics 2003; 112(4): e308.
87. Cohen ER, O'Neill JM, Joffres M, et al. Reporting of informed consent, standard of care and post-trial obligations in global randomized intervention trials: a systematic survey of registered trials. Dev World Bioeth 2009; 9(2): 74-80.
88. Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med 2001; 345(2): 139-42.
89. Bhutta ZA. Ethics in international health research: a perspective from the developing world. Bull World Health Organ 2002; 80(2): 114-20.
90. Kimmelman J. Clinical trials and SCID row: the ethics of phase 1 trials in the developing world. Dev World Bioeth 2007; 7(3): 128-35.
91. Shah S, Elmer S, Grady C. Planning for posttrial access to antiretroviral treatment for research participants in developing countries. Am J Public Health 2009; 99(9): 1556-62.
92. Canino G, Alegria M. Psychiatric diagnosis - is it universal or relative to culture? J Child Psychol Psychiatry 2008; 49(3): 237-50.
93. Stockdale SE, Lagomasino IT, Siddique J, et al. Racial and ethnic disparities in detection and treatment of depression and anxiety among psychiatric and primary health care visits, 1995-2005. Med Care 2008; 46(7): 668-77.
94. Vitiello B. An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 2008; 20(2): 121-6.
95. Wong VC. Use of complementary and alternative medicine (CAM) in autism spectrum disorder (ASD): comparison of Chinese and western culture (Part A). J Autism Dev Disord 2009; 39(3): 454-63.
96. Merton R. The sociology of science: theoretical and empirical investigations. UK: University of Chicago Press 1973.
97. Lenzer J. Truly independent research? BMJ 2008; 337: a1332.
98. Vitiello B. Truly independent research? Treatment for Adolescents with Depression Study (TADS). BMJ 2008; 337: a2070.
99. Angell M. The truth about the drug companies: How. They deceive us and what to do about it. New York: Random House 2004.
100. Magno J, Derivan A, Greenhill LL. Making research data available: an ethical imperative demonstrated by the SSRI debacle. J Am Acad Child Adolesc Psychiatry 2004; 43(5): 512-4.
101. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. BMJ 2003; 326(7400): 1163.
102. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ 2008; 336(7658): 1402-3.
103. Fangerau H. Research ethics, publication ethics and the dialectics of scientists trying not to behave badly. J Public Health 2009; 17(6): 433-4.
104. Okike K, Kocher MS, Wei EX, et al. Accuracy of conflict-ofinterest disclosures reported by physicians. N Engl J Med 2009; 361(15): 1466-74.
105. Weinfurt KP, Hall MA, King NM, et al. Disclosure of financial relationships to participants in clinical research. N Engl J Med 2009; 361(9): 916-21.
106. Grieve J, Tordoff J, Reith D, et al. Effect of the pediatric exclusivity provision on children's access to medicines. Br J Clin Pharmacol 2005; 59(6): 730-5.
107. DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? Clin Pharmacol Ther 2007; 82(5): 488-90.
108. Haefner B. Law and research could add up to profitable niche drugs. Nature 2007; 446(7138): 856.
109. Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des 2004; 10(18): 2231-2238.
110. Maid G, Guerchicoff M, Falconi M, de Arenaza DP. Written consent to use the drug in children: the problem of off-label drugs. Curr Pharm Des 2008; 14(8): 776-781.
111. Vijverberg SJ, Pieters T, Cornel MC. Ethical and social issues in pharmacogenomics testing. Curr Pharm Des 2010; 16(2): 245-252.